Abstract
In this chapter, an overview of in vivo induced antigen technology (IVIAT) and change mediated antigen technology (CMAT) will be presented, including a discussion of the advantages and limitations of these methods. Over fifteen different microbial pathogens have been or are known to be currently studied with these methods. Salient data obtained from the application of IVIAT and/or CMAT to a selection of human and plant pathogens will be summarized. This includes recent reports on Streptococcus pyogenes (Group A) in neurological disorders and invasive diseases, Xylella fastidiosa in Pierces disease, Xanthomonas campestris in bean blight, Salmonella enterica serovar typhi in typhoid fever and Leishmania spp. related infections. Special emphasis will be given to those targets that have been further investigated for the development of novel vaccine, diagnostic and/or antibiotherapy strategies. This encompasses a new point-of-care serological diagnostic test for chronic periodontal diseases. Finally, Mycobacterium tuberculosis in vivo induced products will be described as providing a rational basis for differentiating subjects with primary, dormant or secondary tuberculosis infections, from control subjects who have or did not have prior vaccination with BCG.
Keywords: Virulence, pathogenesis, bacterium, parasite, IVIAT, CMAT, IVET, STM, DFI
Infectious Disorders - Drug Targets
Title: In Vivo Induced Antigen Technology (IVIAT) and Change Mediated Antigen Technology (CMAT)
Volume: 6 Issue: 3
Author(s): Martin Handfield and Jeffrey D. Hillman
Affiliation:
Keywords: Virulence, pathogenesis, bacterium, parasite, IVIAT, CMAT, IVET, STM, DFI
Abstract: In this chapter, an overview of in vivo induced antigen technology (IVIAT) and change mediated antigen technology (CMAT) will be presented, including a discussion of the advantages and limitations of these methods. Over fifteen different microbial pathogens have been or are known to be currently studied with these methods. Salient data obtained from the application of IVIAT and/or CMAT to a selection of human and plant pathogens will be summarized. This includes recent reports on Streptococcus pyogenes (Group A) in neurological disorders and invasive diseases, Xylella fastidiosa in Pierces disease, Xanthomonas campestris in bean blight, Salmonella enterica serovar typhi in typhoid fever and Leishmania spp. related infections. Special emphasis will be given to those targets that have been further investigated for the development of novel vaccine, diagnostic and/or antibiotherapy strategies. This encompasses a new point-of-care serological diagnostic test for chronic periodontal diseases. Finally, Mycobacterium tuberculosis in vivo induced products will be described as providing a rational basis for differentiating subjects with primary, dormant or secondary tuberculosis infections, from control subjects who have or did not have prior vaccination with BCG.
Export Options
About this article
Cite this article as:
Handfield Martin and Hillman D. Jeffrey, In Vivo Induced Antigen Technology (IVIAT) and Change Mediated Antigen Technology (CMAT), Infectious Disorders - Drug Targets 2006; 6 (3) . https://dx.doi.org/10.2174/187152606778249908
DOI https://dx.doi.org/10.2174/187152606778249908 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Rational Approach to Identify Inhibitors of Mycobacterium tuberculosis Enoyl Acyl Carrier Protein Reductase
Current Pharmaceutical Design Recent Developments in Phytosterol Recovery from Oil Deodorizer Distillates
Current Nutrition & Food Science Understanding the Interaction Between Human Serum Albumin and Anti-Bacterial/ Anti-Cancer Compounds
Current Pharmaceutical Design Neuroprotective Mechanisms of Oxygen and Ethanol: A Potential Combination Therapy in Stroke
Current Medicinal Chemistry Therapy of XDR TB with Thioridazine a Drug Beyond Patent Protection but Eligible for Patent “As New Use”
Recent Patents on Anti-Infective Drug Discovery Disorders of Innate Immunity in Human ageing and effects of Nutraceutical Administration
Endocrine, Metabolic & Immune Disorders - Drug Targets Galvez-Markov Network Transferability Indices: Review of Classic Theory and New Model for Perturbations in Metabolic Reactions
Current Drug Metabolism Indolo[3,2-b]quinolines: Synthesis, Biological Evaluation and Structure Activity-Relationships
Mini-Reviews in Medicinal Chemistry Recent Progress of Molecular Docking Simulations Applied to Development of Drugs
Current Bioinformatics Bioinformatics and the Discovery of Novel Anti-Microbial Targets
Current Drug Targets - Infectious Disorders Chemokines and Persistent Inflammation in Rheumatoid Arthritis: Hunting for Therapeutic Targets
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Novel Antibacterial Compounds and their Drug Targets - Successes and Challenges
Current Medicinal Chemistry Current Status of Anti-Tuberculosis Therapy: A Patent Analysis
Recent Patents on Anti-Infective Drug Discovery Targeting Cancer: The Challenges and Successes of Structure-Based Drug Design Against the Human Purinome
Current Topics in Medicinal Chemistry Isoprenoid Biosynthesis of the Apicoplast as Drug Target
Current Drug Targets Antibacterial Effects of Carbon Monoxide
Current Pharmaceutical Biotechnology CRISPeering: Bioengineering the Host Cells through CRISPRCas9 Genome Editing System as the Next-generation of Cell Factories
Recent Patents on Biotechnology Hodgkin Lymphoma in HIV Positive Patients
Current HIV Research Cosignaling Complexity Gets More Convoluted: The Emerging Importance of the B7-Like Butyrophilin Family of Immune Regulators
Current Immunology Reviews (Discontinued) Nebulizer Therapy in Pulmonology: Review of the Literature
Current Respiratory Medicine Reviews